The effect of omeprazole on the pharmacokinetics of dasatinib (BMS-354825) in healthy subjects

Trial Profile

The effect of omeprazole on the pharmacokinetics of dasatinib (BMS-354825) in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2009

At a glance

  • Drugs Dasatinib; Omeprazole
  • Indications Acute lymphoblastic leukaemia; Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Peptic ulcer; Prostate cancer; Zollinger-Ellison syndrome
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 14 Jul 2008 Actual patient number (49) added as reported by ClinicalTrials.gov.
    • 14 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 May 2008 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top